510(k) · Cleared
Cleared0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Becton, Dickinson and Company · NGT Saline, Vascular Access Flush
Cleared on Dec 2, 2025 as substantially equivalent to K161552 (Becton, Dickinson and Company, 2017) after a 253-day review. Its family tree reaches back 5 generations to 2001.
- Decided
- Dec 2, 2025
- Review
- 253 days
- Class
- Class II
- Product code
- NGT
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 5 generations to K003553 (2001). No later device cites it as a predicate yet.
- Root · 5 generations backK003553 0.9% Sodium Chloride Injection, Usp BD Pre-Filled Flush SyringeBd Becton Dickinson Vacutainer Systems Preanalytic · 2001
- 4 generations backK042061 0.9% Sodium Chloride Injection, Usp BD Postflush SF Flush SyringeBecton Dickinson · 2004 · Recalled
- 3 generations backK121050 0.9% Sodium Chloride Injection Usp BD Posiflush Flush Syringe, SF…Becton, Dickinson & CO · 2013 · Recalled
- 2 generations backK141311 0.9% Sodium Chloride Injection, Usp BD Posiflush; SP Syringe, SF…Becton, Dickinson and Company · 2014
- 1 generation backK161552 0.9% Sodium Chloride Injection, USP BD PosiFlush SP SyringeBecton, Dickinson and Company · 2017 · Recalled
- This deviceK250884 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP SyringeBecton, Dickinson and Company · 2025
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −5 | K003553 | 0.9% Sodium Chloride Injection, Usp BD Pre-Filled Flush Syringe | Bd Becton Dickinson Vacutainer Systems Preanalytic | 2001 | — |
| −4 | K042061 | 0.9% Sodium Chloride Injection, Usp BD Postflush SF Flush Syringe | Becton Dickinson | 2004 | 13 |
| −3 | K121050 | 0.9% Sodium Chloride Injection Usp BD Posiflush Flush Syringe, SF Flush Syringe | Becton, Dickinson & CO | 2013 | 1 |
| −2 | K141311 | 0.9% Sodium Chloride Injection, Usp BD Posiflush; SP Syringe, SF Syringe | Becton, Dickinson and Company | 2014 | — |
| −1 | K161552 | 0.9% Sodium Chloride Injection, USP BD PosiFlush SP Syringe | Becton, Dickinson and Company | 2017 | 3 |
| 0 (this device) | K250884 | 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe | Becton, Dickinson and Company | 2025 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in NGT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new NGT device
- #1 K213522 AMSafe Pre-Filled Normal Saline Flush Syringescore 10.3 · 5 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K161552 | 0.9% Sodium Chloride Injection, USP BD PosiFlush SP SyringeSummary page 5…Class II Product Code: NGT Classification Panel: General Hospital Predicate Device 510(k) Number: K161552 Trade Name: 0.9 % Sodium Chloride Injection, USP, BD… | 2017 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 24 years and passes through 4 companies; a new generation was cleared every 3.4 years on median.
- 3 of the 5 ancestors have a recall of any class.
- 1 other device also cites its predicate K161552.
How does its category compare?
All NGT devicesNGT Saline, Vascular Access Flush: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.
FDA decisions per year · NGT
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · NGT
142in 2023
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · NGT
1in 2025
Class I (6 since 2007) Class II/III not classified
Adverse event reports per year · NGT
212in 2025
MAUDE reports naming product code NGT, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 2 | 31 |
| 2008 | 1 | — | 0 | 64 |
| 2009 | 1 | — | 1 | 18 |
| 2010 | 2 | — | 7 | 23 |
| 2011 | 3 | 219 | 1 | 20 |
| 2012 | 4 | 106 | 1 | 5 |
| 2013 | 1 | — | 1 (1) | 25 |
| 2014 | 3 | 87 | 0 | 25 |
| 2015 | 1 | — | 0 | 14 |
| 2016 | 1 | — | 1 (1) | 82 |
| 2017 | 2 | — | 0 | 56 |
| 2018 | 1 | — | 0 | 270 |
| 2019 | 2 | — | 2 | 340 |
| 2020 | 2 | — | 0 | 322 |
| 2021 | 0 | — | 1 (1) | 566 |
| 2022 | 3 | 151 | 1 | 282 |
| 2023 | 6 | 142 | 3 (2) | 313 |
| 2024 | 1 | — | 0 | 332 |
| 2025 | 1 | — | 1 | 212 |
| 2026 | 0 | — | 1 (1) | — |
What is it indicated for?
The 0.9% Sodium Chloride Injection, USP, BD PosiFlush SP Syringe is intended to be used only for the flushing of indwelling vascular access devices.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K250884 · printed Nov 4, 2026
Cite this page
510(k) Report. “K250884: 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K250884
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026